左旋多巴联合地昔帕明治疗帕金森患者抑郁症状的效果研究  

Efficacy of Benserazide and Desipramine on the Improvement of Depressive Symptoms and Quality of Life in Patients with Parkinson's Disease

作　　者：焦凤有 

机构地区：[1]广东省肇庆市第二人民医院神经内科,广东肇庆526060

出　　处：《热带医学杂志》2012年第11期1359-1361,共3页Journal of Tropical Medicine

摘　　要：目的探讨左旋多巴联合地昔帕明改善帕金森病(PD)患者的抑郁症状及生活质量的效果。方法将伴有严重抑郁的帕金森病患者108例随机分为治疗组(51例)和对照组(57例),治疗组服用地昔帕明和左旋多巴,对照组服用安慰剂及左旋多巴,于治疗14d和30d后分别利用蒙哥马利抑郁量表(MADRS)和帕金森氏症生活品质问卷(PDQ-39)对两组患者抑郁症状和生活质量进行评估。结果在治疗前及治疗14d后,两组的MADRS和PDQ39评分差异均无统计学意义(P>0.05),但在治疗1个月后,治疗组的MADRS评分(33.33±4.07)及PDQ39评分(36.20±6.15)均显著低于对照组的(38.21±7.12)分和(42.53±9.61)分,差异有统计学意义(P<0.05);地昔帕明对轻、中度抑郁患者的治疗效果优于重度抑郁组P<0.05)。结论左旋多巴联合地昔帕明能在短期内有效改善PD患者的抑郁症状和生活质量,地昔帕明对轻、中度抑郁患者有较好的疗效。Objective To explore the efficacy of Benserazide and Desipramine on depressive symptoms and the quality of life in patients with Parkinson＇s disease （PD）. Methods 108 PD patients who had depressive symptoms were recruited from our hospital. All patients were randomized into two groups： treatment group （51 patients） and the control group （57 patients）. Participants of treatment group had taken Desipramine and Benserazide, and control group had taken placebo and Benserazide.To evaluate the degree of improvement, depressive symptoms were measured with Montgomery asberg depression rating scale（MADRS） and the quality of life with PDQ-39 at day 14 and 30. Results The two groups have insignificant differences of scores of PDQ-39 and MADRS before and after 14 days treatment（P〉0.05）. But after 30 days treatment, the scores of PDQ-39 and MADRS in treatment group were significantly lower than those of control group（P〈0.05）. Compared with severe depression, Desipramine had a more favorable effects on mild and moderate depression（P〈0.05）. Conclusions Treatment with Desipramine combined with Benserazide can improve the depressive symptoms and the quality of life in patients in a short time, Desipramine had more favorable effects on mild and moderate depression patients.

关 键 词：地昔帕明 左旋多巴 帕金森病 抑郁症状 

分 类 号：R745[医药卫生—神经病学与精神病学]